A venture capital firm based in the USA with a presence in China, has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. The firm seeks to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies globally, with a focus on those in USA, Europe, and China.
The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.
The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Author: Next Phase Admin
Hot Investor Mandate: CVC of Global Medical Device Company Invests Strategically in Digital Healthcare Solutions & Life Science Tools
A firm is focused on early stage investment to support founders and their teams advance healthcare solutions. The team originated at a global medical device company that has worked with researchers and physicians for more than 50 years to develop more effective therapeutic tools. The firm participates in pre-seed, seed and A rounds as a dedicated partner working closely with startups to advance technologies and build companies. Initial investment ranges from $250k-$1M. The firm has a global presence and is open to early-stage companies from around the world.
The firm’s investment focus is on 1) digital solutions to improving healthcare and 2) the development of life science tools to enable the production of advanced therapeutics.
The firm has no strict requirements for companies or management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
2022 Fundraising is Here – Are you?
By Rory McCann, Marketing Manager & Conference Producer, LSN
Only a few days into the new year and already one of the biggest fundraising events of the year is starting. Digital RESI JPM, January 11-13 partnering is open and vibrant with hundreds of attendees taking advantage of the opportunities available to fundraising entrepreneurs in 2022. There is still time to sign up for early-stage companies seeking capital, licensing, and strategic partnerships, but even more importantly is the yearlong ecosystem of partnering that companies at all stops along their early-stage journey can take advantage of.
If 2022 is your year to kick your fundraising into high gear, check out the Digital RESI JPM agenda, as well as the plethora of events and services available to help you meet your goals and be successful in the new year.
| Tuesday (1/11) | Wednesday (1/12) | Thursday (1/13) | |
| 10AM EST | Innovator’s Pitch Challenge #1 Devices & Diagnostics | Family Offices Panel | Innovator’s Pitch Challenge #8 Longevity-Devices & Digital Health |
| Innovator’s Pitch Challenge #5 Oncology Therapeutics & AI Drug Discovery Applications | |||
| 11AM EST | Medical Devices Investor Panel | Defining and Funding Age-Tech Innovations Panel | Diagnostics Investor Panel |
| 12PM EST | Negotiating Term Sheets  |
Licensing in Life Sciences  |
How to Evaluate Your Banking Partner Workshop |
| 1PM EST | Innovator’s Pitch Challenge #2 Therapeutics | Innovator’s Pitch Challenge #6 Diagnostics & Digital Health | Innovator’s Pitch Challenge #9 Devices and R&D Services |
Fundraising Challenges and Highlights of First-Time Founders & CEOs |
|||
| 2PM EST | The Regulatory Pathway for AI in Healthcare Panel | Digital Health Investor Panel | Emerging Products and Technologies for Aging at Home Panel |
| 3PM EST | Big Pharma Panel | The Early Stage Pivot Panel | Corporate VC Panel |
| Innovator’s Pitch Challenge #3 Oncology Diagnostics | Innovator’s Pitch Challenge #10 Medical Devices | ||
| 4PM EST | Tales from the Road: Age-Tech Innovators on their Fundraising Journey | Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey | Tales from the Road: AI Innovators on their Fundraising Journey |
| 5PM EST | Innovator’s Pitch Challenge #4 AI-Devices & Digital Health | Innovator’s Pitch Challenge #7 Therapeutics | Innovator’s Pitch Challenge #11 Oncology Therapeutics |
| Longevity Investors Share Their Investment Thesis | Longevity Entrepreneurs Discuss Their New Products |
- Digital RESI Conference Series and Innovator’s Pitch Challenge
- Digital RESI Sponsorship
- Life Science Nation Investor Database (Get a free demo today!)
- Life Science Nation BD Database (Get a free demo today!)
- Life Science Nation Branding & Messaging
Digital RESI JPM 2022 IPC Finalists
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Happy New Year! Life Science Nation (LSN) is excited to kick off 2022 with Digital RESI JPM next week. A record number of early-stage life science and healthcare companies applied to participate in the Innovator’s Pitch Challenge (IPC) at the upcoming RESI.
Our 54 finalist companies will have a dedicated webpage that includes the company’s key marketing collateral including a short pitch video, available for viewing to all RESI attendees. Most importantly, these companies have been assigned to a 1-hour live Q&A session based on sector/technology, interacting with investors and strategic partners who will ask them targeted questions and provide feedback on their pitches.
We are delighted to feature companies across a wide variety of sectors, including therapeutics, devices, diagnostics, and digital health. See the participating companies below:
Digital RESI JPM 2022 IPC Finalists
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Investors at Next Week’s Digital RESI JPM
By Joey Wong, Investor Research Analyst, LSN
Life Science Nation (LSN)’s first and largest event of the year, Digital RESI JPM 2022, is coming up in less than a week. With most of the major events happening around JPM going virtual, LSN has been overwhelmed by the number of registration requests that we have been receiving, as we do our best to ensure that every investor is a direct, active investor who looks at the early-stage life science and healthcare space. With 300+ investors confirmed to attend, including large pharma/medtech, family offices, corporate venture capitals funds, and more, this digital conference is a great opportunity to kick off your fundraising campaign and start a dialog with potential investors and strategic partners in 2022. Register now to meet with these investors:
Hot Investor Mandate: USA Firm With Several Billion AUM Seeks Global Healthcare Opportunities, With Strong Interests in Nucleic Acid-Based Therapeutics and Life Science Tools
A multi-billion AUM firm based in the USA is known for investing in technologies that change paradigms. The firm is currently investing out of a $1 billion venture fund for later stage investments and a $400 million for seed-stage investments. The firm has invested across a multitude of industries, including healthcare. Within healthcare, the firm is agnostic, choosing to select companies based on their potential impact. The firm will invest globally and generally prefer Seed and Series A opportunities for new investments.
While the firm is agnostic to sector and indication, the firm does have several areas of particularly high interest. Currently, the firm is interested in nucleic acid-based technologies and therapeutics, manufacturing and automation tools, and discovery tools. While the firm is open to any indication, the firm does prefer to invest in less crowded disease areas.
The firm places a strong emphasis on the team when investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Corporate Venture Arm Strategically Invests in Devices and Digital Health Companies Dedicated to Elderly Care and Improving Quality of Life
The corporate venture arm of a senior living community invests strategically in companies that can enhance their services or the elderly population quality of life in general, including in healthcare. Within healthcare, the firm is willing to invest in digital health, medical devices and diagnostic/monitoring technologies, but will not invest in therapeutics. The firm generally invests in seed to series A, and will occasionally act as a company builder, co-founding a company around a promising technology. In an initial investment, the firm will generally invest no more than $.5M, but has the ability to invest in follow-on rounds. As a strategic investor, in addition to capital, the firm can employ their facilities for pilot programs, and will occasionally do so before investing. The firm is primarily interested in Israeli companies, but will invest globally.
The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.
The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
